Connect to share and comment

Generics file response to Teva in Copaxone patent fight

By Lawrence Hurley WASHINGTON (Reuters) - Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

Poland extends corruption probe into Britain's GSK

Polish prosecutors said Monday they have extended a probe into allegations that British pharmaceutical giant GlaxoSmithKline bribed doctors into promoting one of its drugs. The company also faces a bribery probe in China and last week announced it was investigating alleged corruption by staff at its pharmaceuticals division in Iraq.

Poland extends corruption probe into Britain's GSK

Polish prosecutors said Monday they have extended a probe into allegations that British pharmaceutical giant GlaxoSmithKline bribed doctors into promoting one of its drugs. The company also faces a bribery probe in China and last week announced it was investigating alleged corruption by staff at its pharmaceuticals division in Iraq.

Britain's GSK reveals new bribery probe in Iraq

British drugmaker GlaxoSmithKline (GSK) is investigating alleged corruption by staff at its pharmaceuticals division in Iraq, the group announced on Monday. GSK, which already faces a bribery probe in China, stressed that it would not tolerate illegal behaviour by staff. "We are investigating allegations of improper conduct in our Iraq business. We have zero tolerance for unethical or illegal behaviour," a spokesman told AFP.

Britain's GSK reveals new bribery probe in Iraq

British drugmaker GlaxoSmithKline (GSK) is investigating alleged corruption by staff at its pharmaceuticals division in Iraq, the group announced on Monday. GSK, which already faces a bribery probe in China, stressed that it would not tolerate illegal behaviour by staff. "We are investigating allegations of improper conduct in our Iraq business. We have zero tolerance for unethical or illegal behaviour," a spokesman told AFP.

Novartis' meningitis B vaccine wins breakthrough therapy status in U.S.

ZURICH (Reuters) - Novartis said U.S. health regulators have granted the Swiss drugmaker's meningitis B vaccine Bexsero breakthrough therapy status. The Basel-based company in a statement on Monday said it plans to file for U.S. approval of Bexsero as early as the second quarter of this year.

Novartis' top Japan executives quit over cancer drug scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. The company also said it was freezing funding for clinical trials in the country in the wake of the scandal, which David Epstein, head of the firm's pharmaceutical division, branded "unacceptable and a clear violation of our code of conduct". Epstein told a press briefing in Tokyo that the senior managers "resigned, they are out of the company".

Novartis' top Japan executives quit over cancer drug scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. The company also said it was freezing funding for clinical trials in the country in the wake of the scandal, which David Epstein, head of the firm's pharmaceutical division, branded "unacceptable and a clear violation of our code of conduct". Epstein told a press briefing in Tokyo that the senior managers "resigned, they are out of the company".

Novartis replaces top Japan executives over drug trial scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. David Epstein, the head of the firm's pharmaceutical division, told a news briefing in Tokyo that the senior managers "resigned, they are out of the company", adding that "this kind of behaviour is unacceptable and a clear violation of our code of conduct". "I'd like to once again apologise for Novartis' involvement in this issue," Epstein told reporters.

FDA bans imports from Canadian drugmaker Apotex's India plant

MUMBAI (Reuters) - The U.S. Food and Drug Administration banned imports from Canadian drugmaker Apotex Inc's manufacturing plant in India for not complying with quality standards, the latest in a series of sanctions against medicines produced in India. Drugs made at the plant, based in the southern Indian city of Bangalore, will be detained without physical examination because the factory did not meet the FDA's good manufacturing practices, the agency said on its website on Wednesday.
Syndicate content